Literature DB >> 19346873

Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.

Christian M Capitini1, Laurence J N Cooper, R Maarten Egeler, Rupert Handgretinger, Franco Locatelli, Paul M Sondel, Crystal L Mackall.   

Abstract

The first annual conference on immunotherapy in pediatric oncology was held in Bethesda, MD, from September 9 to 10, 2008 to discuss the state-of-the-art of immunotherapeutic strategies currently being explored in pediatric oncology. Major topics included targeting cell surface receptors, understanding and improving T-cell-based therapies, augmenting innate immune strategies, and enhancing graft-versus-leukemia for pediatric malignancies. As can be seen in the summaries of the individual presentations, significant progress has been made in developing preclinical models of pediatric tumors and a variety of novel immunobiologic therapies are approaching, or already in, the clinic. Although there is much excitement about the potential utility of these agents, a great deal of challenges lie ahead in improving the efficacy of each of these modalities and getting them to patients in a timely fashion. The resulting discussions will hopefully lead to new collaborations and insight for further translational and clinical studies.

Entities:  

Mesh:

Year:  2009        PMID: 19346873      PMCID: PMC2714285          DOI: 10.1097/MPH.0b013e31819a5d8d

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  54 in total

1.  Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group.

Authors:  O Krejci; V H J van der Velden; P Bader; H Kreyenberg; N Goulden; J Hancock; M W Schilham; A Lankester; T Révész; T Klingebiel; J J M van Dongen
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

2.  9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.

Authors:  N V Koshkina; E S Kleinerman; C Waidrep; S F Jia; L L Worth; B E Gilbert; V Knight
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

3.  Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.

Authors:  B H Kushner; K Kramer; N K Cheung
Journal:  J Clin Oncol       Date:  2001-11-15       Impact factor: 44.544

4.  Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome.

Authors:  Marco Zecca; Arcangelo Prete; Roberto Rondelli; Edoardo Lanino; Adriana Balduzzi; Chiara Messina; Franca Fagioli; Fulvio Porta; Claudio Favre; Andrea Pession; Franco Locatelli
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

5.  Escape from immune surveillance does not result in tolerance to tumor-associated antigens.

Authors:  Fraia Melchionda; Melissa K McKirdy; Filomena Medeiros; Terry J Fry; Crystal L Mackall
Journal:  J Immunother       Date:  2004 Sep-Oct       Impact factor: 4.456

6.  Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases.

Authors:  Shu-Fang Jia; Laura L Worth; Charles L Densmore; Bo Xu; Xiaoping Duan; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

7.  RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy.

Authors:  Christina M Coughlin; Barbara A Vance; Stephan A Grupp; Robert H Vonderheide
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

8.  T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.

Authors:  Laurence J N Cooper; Max S Topp; Lisa Marie Serrano; Sergio Gonzalez; Wen-Chung Chang; Araceli Naranjo; Christine Wright; Leslie Popplewell; Andrew Raubitschek; Stephen J Forman; Michael C Jensen
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

9.  Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

Authors:  Barbara Savoldo; Cliona M Rooney; Antonio Di Stasi; Hinrich Abken; Andreas Hombach; Aaron E Foster; Lan Zhang; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2007-05-16       Impact factor: 22.113

10.  Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Authors:  Catherine M Bollard; Stephen Gottschalk; Ann M Leen; Heidi Weiss; Karin C Straathof; George Carrum; Mariam Khalil; Meng-fen Wu; M Helen Huls; Chung-Che Chang; M Victoria Gresik; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

View more
  2 in total

Review 1.  Immunotherapy of childhood cancer: from biologic understanding to clinical application.

Authors:  Alan S Wayne; Christian M Capitini; Crystal L Mackall
Journal:  Curr Opin Pediatr       Date:  2010-02       Impact factor: 2.856

Review 2.  Immune-based therapeutics for pediatric cancer.

Authors:  Christian M Capitini; Crystal L Mackall; Alan S Wayne
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.